Program
PI3K p110beta/delta Inhibitor CVL237
Also written as “CVL237 tablets” and “KA2237”.
Its studies are mostly in Stomach Neoplasms · Lymphoma, B-Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Convalife (Shanghai) | 33 open or running | phase 3since Feb 18, 2024 | Nov 26, 2023 | Jan 9, 2028phase 2 · NCT07446049 |
| Karus Therapeutics | 10 open or running | phase 1since Jan 29, 2016 | Jan 29, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 29, 2016First study: phase 1 study in Lymphoma, B-CellNew to Karus TherapeuticsKarus Therapeutics · NCT02679196 · 23 enrolled · United States
- Nov 26, 2023Convalife (Shanghai)’s first study: phase 2 study in Stomach NeoplasmsNew to Convalife (Shanghai)Convalife (Shanghai) · NCT06183736 · 98 planned · China
- Feb 18, 2024Phase 3 study in Hereditary Sensory and Autonomic NeuropathiesConvalife (Shanghai) · NCT06293716 · 35 planned · China
- Jun 26, 2025Phase 2 study in Stomach NeoplasmsConvalife (Shanghai) · NCT07446049 · 180 planned
Ahead
- Jan 9, 2028Primary completion: phase 2 study in Stomach NeoplasmsConvalife (Shanghai) · NCT07446049
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07446049Stomach Neoplasms | 2 | Not yet recruiting | Convalife (Shanghai) | Jan 9, 2028 | 180 |
| NCT06293716Hereditary Sensory and Autonomic Neuropathies · China | 3 | Not yet recruiting | Convalife (Shanghai) | Dec 29, 2025 | 35 |
| NCT06183736Stomach Neoplasms · China | 2 | Not yet recruiting | Convalife (Shanghai) | Jun 30, 2025 | 98 |
| NCT02679196Lymphoma, B-Cell · United States | 1 | Completed | Karus Therapeutics | Dec 24, 2018 | 23 |
How it is read
Names in the registry
- “CVL237 tablets”, 3 entries
- “KA2237”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 2 studies
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.